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SUMMARY 
In a cluster-randomised trial of intensive versus standard anthelminthic treatment, intensive 
treatment reduced Schistosoma mansoni intensity and hookworm prevalence, but had no effect on 
atopy, allergy-related disease or helminth-related pathology. Additional interventions are required to 
reduce transmission in schistosomiasis hot-spots. 
 
Running title: Anthelminthic treatment and allergy  
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ABSTRACT 
Background 
Allergy-related disease is increasing in low-income countries.  Parasitic helminths, common in these 
settings, may be protective. We hypothesised that intensive community-wide anthelminthic mass drug 
administration (MDA) would increase allergy-related diseases, while reducing helminth-related 
morbidity.  
Methods  
In an open, cluster-randomised trial (ISRCTN47196031), we randomised 26 high-schistosomiasis-
transmission fishing villages, Lake Victoria, Uganda, in a 1:1 ratio to receive community-wide intensive 
(quarterly single-dose praziquantel plus albendazole daily for three days) or standard (annual 
praziquantel plus six-monthly single-dose albendazole) MDA.  Primary outcomes were recent wheeze, 
skin prick test positivity (SPT) and allergen-specific immunoglobulin E (asIgE) after three years’ 
intervention.  Secondary outcomes included helminths, haemoglobin and hepatosplenomegaly. 
Results 
The outcome survey comprised 3350 individuals. Intensive MDA had no effect on wheeze, SPT or 
asIgE (risk ratios (95% confidence intervals): 1.11 (0.64,1.93), 1.10 (0.85,1.42) and 0.96 (0.82,1.12), 
respectively). Intensive MDA reduced S. mansoni infection intensity: prevalence from Kato-Katz 
examination of one stool sample was 23% versus 39% (RR 0.70 (0.55,0.88)), but the more-sensitive 
urine circulating cathodic antigen test remained positive in 85% participants in both trial arms.  
Hookworm prevalence was 8% versus 11% (RR 0.55 (0.31,1.00)).  There were no differences in 
anaemia or hepatospenomegaly between trial arms. 
Conclusions 
Despite reductions in S. mansoni intensity and hookworm prevalence, intensive MDA had no effect on 
atopy, allergy-related disease or helminth-related pathology. This could be due to sustained low-
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intensity infections, thus a causal link between helminths and allergy outcomes cannot be discounted. 
Intensive community-based MDA has limited impact in high-schistosomiasis-transmission fishing 
communities, in the absence of other interventions. 
Key words: Helminths, Schistosoma mansoni, mass drug administration, allergy-related disease, 
Africa. 
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INTRODUCTION 
The prevalence of allergy-related diseases (ARD) such as eczema, rhinitis and asthma increased 
rapidly in high-income countries in the twentieth century [1] and is now increasing in tropical, low-
income countries (LICs) [2]. Nevertheless, populations in LICs, particularly in rural settings, remain 
relatively protected [3]. Understanding this phenomenon is crucial to elucidating causes, and 
improving prevention, of ARD.  
By contrast, LICs carry the largest burden of parasitic helminth infections: these are associated with 
some severe and much subtle morbidity [4, 5]. Major anthelminthic Mass Drug Administration (MDA) 
has taken place in the last decade but, although prevention of severe helminth-induced morbidity is 
important, wider benefits [6], and sustainability of helminth control by MDA [7, 8], have been 
questioned.  
Certain helminth antigens are highly homologous to allergens; immunoglobulin (Ig)-E and the atopic 
pathway are presumed to have evolved to protect mammals against such organisms [9]. Parasitic 
helminths must modulate such responses to survive within mammalian hosts. Animal and human 
epidemiological and in vitro studies indicate that, through by-stander effects of such 
immunomodulation, chronic helminth infection protects against atopy and ARD [10]. If helminths 
protect against ARD, MDA programmes may adversely affect these outcomes. Observational studies, 
many of which indicate an inverse association between helminths and ARD, are subject to confounding 
and reverse causation; therefore several groups have investigated effects of anthelminthic treatment 
on ARD in clinical trials. Some studies show increased atopy after anthelminthic intervention, but two 
large, school-based, individually-randomised intervention trials focussing on soil-transmitted 
helminths (STH) reported no effect on atopy or ARD [11, 12]. A recent household-randomised trial of 
intensive albendazole for STH showed no effect on ARD but upregulated pro-inflammatory responses, 
and reduced immunoregulatory molecules [13].  
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East African fishing communities bear an intense schistosomiasis burden [14]. During Schistosoma 
mansoni infection, adult worms reside in mesenteric blood vessels and eggs are excreted through 
intestinal mucosa, causing intestinal and tissue (notably liver) pathology [5]. Schistosoma infection has 
shown even stronger inverse associations with atopy than STH [15] and there is evidence of increased 
SPT reactivity with treatment [16], but no large-scale randomised trial on allergy-related effects of 
intensively treating schistosomiasis has been conducted.   
We undertook the Lake Victoria Island Intervention Study on Worms and Allergy-related diseases 
(LaVIISWA; ISRCTN47196031) [17], a cluster-randomised trial of extended (three-year) intensive 
versus standard anthelminthic intervention, to assess the causal role of helminths in allergy-related 
outcomes and the benefits of intensive intervention for helminth-related morbidity in a 
schistosomiasis “hot-spot”.   
 
METHODS 
Design and setting 
This was a two-arm, open, cluster-randomised trial of intensive versus standard anthelminthic 
treatment conducted among fishing villages in the Koome islands, Lake Victoria, Uganda between 
September 2012 and August 2016. The protocol has been published [17]. Twenty-six villages were 
randomised 1:1 to intensive or standard intervention. Village-level cluster-randomisation aimed to 
minimise contamination from re-infection by untreated neighbours. Before the study, annual 
praziquantel treatment was offered to these communities, but hampered by logistics.  In our baseline 
survey, 17% participants reported treatment in the past year [17]. 
Interventions 
Standard intervention (Uganda Ministry of Health (MoH) guidelines) was annual single-dose 
praziquantel 40mg/kg (Cipla; CSPC OUYI Pharmaceuticals, India; AGOG Pharma, India), estimated by 
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height-pole, to community members ≥94cm plus six-monthly single-dose albendazole 400mg (CSPC 
OUYI Pharmaceuticals, India; AGOG Pharma, India; Medreich, India) to all aged ≥1-year. Intensive 
intervention was quarterly single-dose praziquantel 40mg/kg (estimated by extended height-pole for 
individuals ≥60cm to allow treatment of younger children) [18] plus quarterly triple-dose albendazole 
(400mg daily, three days) to all aged ≥1-year. Pregnant women were included in both arms, receiving 
single-dose albendazole [19, 20].  
Treatment, distributed house-to-house in collaboration with the Uganda MoH Vector Control Division, 
was directly observed and documented against household registers, with the exception of post-day-
one albendazole in the intensive arm.  
Participants and surveys 
Leaders of all 27 Koome fishing villages gave written consent for village participation. Allocated 
interventions were given to all community members (of eligible age and height) unless absent, sick or 
refused.  
Household-based surveys were conducted at baseline [21] and after three years’ intervention.  All 
primary, and most secondary, outcomes were assessed in both baseline and outcome surveys.  Smaller 
surveys were conducted at years one and two to assess helminth trends (Supplementary Figure).  
Separate random household samples were selected for each survey (overlap was possible). There was 
no individual participant follow-up. Surveys were conducted immediately prior to respective quarterly 
treatments.  
Household registers were updated before each survey.  Villages generally comprised an intensely 
populated centre and scattered periphery. Peripheral households were excluded from surveys to avoid 
contamination from neighbouring villages, but received allocated interventions.  
Baseline survey methods (previously reported) were similar to the three-year outcome survey 
described below [21]. For interim surveys, stool and blood samples were collected from community 
members selected using a two-stage method: one person was randomly selected from each of 15 
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randomly selected households per village. For the three-year survey, 70 households per village were 
randomly selected using a Stata program (StataCorp, College Station, USA).  In selected households, all 
members ≥1-year were invited to participate. Household heads gave permission for household 
participation, and details (age, sex) of all members.  Written informed consent was obtained from all 
adults and emancipated minors and from parents/guardians for children, with additional assent from 
children ≥8 years. For each participant, a questionnaire was completed; examination and SPT 
performed; and blood, urine and one stool sample obtained.  Abdominal ultrasonography was 
performed on children. 
Outcomes 
Primary outcomes were recent (last 12 months) self-reported wheeze stratified by age (<5 years, ≥5 
years), SPT positivity to mites (Dermatophagoides mix, Blomia tropicalis) and German cockroach 
(Blattella germanica), and allergen-specific IgE (asIgE) to Dermatophagoides and German cockroach 
(common allergens in Uganda  [22]). Secondary outcomes were visible flexural dermatitis (assessed 
using standardised procedures), helminth infections, haemoglobin, growth (height-for-age (<20 
years), weight-for-age (<11 years), weight-for-height (<6 years) z-scores) and hepatosplenomegaly 
(by palpation). An additional secondary outcome, schistosomiasis-related liver and spleen morbidity 
assessed by abdominal ultrasonography (<18 years), was included after trial interventions 
commenced when additional funding became available. Exploratory outcomes were recent urticaria 
and rhinitis. For logistical reasons we could not provide infant vaccines ourselves, or obtain post-
immunisation samples at consistent timepoints, so planned vaccine response secondary outcomes are 
not reported. Details on outcome ascertainment are provided (Supplementary Methods). 
Randomisation 
At a public ceremony, one village was randomly selected for piloting while 26 were randomised 1:1, 
using restricted randomisation to balance village size, prior praziquantel treatment and distance from 
sub-county health centre [17] (Supplementary Methods).  
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Statistical methods 
For the outcome survey, we planned to sample 1540 individuals per arm (Supplementary Methods). 
Data were analysed using Stata v14.0. Baseline characteristics were tabulated. Characteristics of 
survey participants were compared with those of non-participants by chi-squared tests. Treatment 
uptake was calculated, by village and treatment round, as the number of people receiving treatment 
divided by the total number of residents. 
Trial analyses were done at cluster-level. Crude and adjusted analyses (adjusting for sex, age and the 
corresponding baseline summary measure of the outcome, where available) were performed. For 
binary outcomes, risk ratios (RR) were calculated as the mean of the intensive arm cluster proportions 
divided by the mean in the standard arm, with 95% confidence intervals (CI) calculated using a Taylor 
series approximation for the standard error, and p-values from unpaired t-tests. Where the 
distribution of cluster proportions was skewed, log-cluster proportions were compared and results 
back-transformed. A two-stage approach was used for adjusted analyses [23] (Supplementary 
Methods).  
For continuous outcomes, intervention effects were quantified as differences in mean outcome 
between trial arms, with 95% CIs calculated using the t-distribution. Non-normally distributed 
continuous outcomes were log-transformed and results back-transformed to obtain geometric mean 
ratios. For ordered categorical outcomes, a proportional-odds model was used.  
Trial analyses were conducted in two populations: the primary analysis population (“intention-to-
treat”) included all individuals. The secondary analysis population comprised all individuals who had 
lived in their village throughout (or were born into their village during) the intervention period (“per 
protocol”).   
Using a cluster-level approach [24], we conducted post-hoc subgroup analyses by age group (<4 years, 
≥4 years) for primary outcomes, to assess whether intervention effects differed among those exposed 
to differential anthelminthic interventions from birth.   
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Ethics statement 
Ethical approval was given by the Uganda Virus Research Institute (GC127), Uganda National Council 
for Science and Technology (HS 1183) and London School of Hygiene & Tropical Medicine (6187). 
 
RESULTS 
Participants and intervention uptake 
Characteristics assessed in the baseline survey (October 2012-July 2013), were balanced between trial 
arms, with the exception that, compared to villages in the intensive arm (“intensive villages”), villages 
in the standard arm (“standard villages”) had fewer public toilets but contained more households with 
private toilets [17].  
Figure 1 summarises treatment uptake. Both praziquantel and albendazole uptake increased during 
the trial. Mean uptake per round was 63% for praziquantel and 64% for albendazole (intensive 
villages), compared to 56% and 73% (standard villages).  In standard villages, albendazole uptake was 
lower in treatment rounds where praziquantel treatment was also given.  Reported receipt of ≥1dose 
of praziquantel in the preceding year was higher in intensive, compared to standard, villages (93% 
versus 75%). Reported receipt of ≥1 dose of albendazole was universally high (99% versus 98%). 
Between September 2015 and August 2016, 70 households from each village were randomly selected 
for the outcome survey (Figure 2); 84 (5%) refused, 17 (1%) consented but no demographic data were 
captured; for 300 (17%) no members could be contacted. The remaining 1419 participating 
households contained 3566 residents aged ≥1-year. Overall, 3350 (94%) household members 
provided data for at least one primary outcome (recent wheeze 3323 (99%), SPT 3037 (91%), IgE 
2955 (88%)), with numbers balanced between trial arms (Figure 2). Further details of participant 
characteristics are provided (Supplementary Material). 
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Outcome survey participant characteristics were comparable between trial arms (Table 1). Only eight 
villages had access to any non-lake water supply, with public toilets available in 11 villages, and 
private toilet access limited. Participant median age was 24 years (IQR: 8-34); 52% were male.  Most 
participants (71%) had lived in their village throughout the trial.  Migration between trial arms was 
low (1.5%). Adult HIV prevalence was 22%; reported maternal history of allergy, eczema or asthma 
was 16%. 
Impact of intensive versus standard anthelminthic treatment on primary outcomes 
Prevalence of wheeze among ≥5-year-olds was 3%, with little difference between trial arms (Table 2). 
Nine individuals <5-years reported wheeze; no formal analysis was done for this outcome. Regarding 
atopy, 19% participants had a positive SPT to ≥1 allergen.  Of those tested using ImmunoCAP, 54% 
were positive (IgE>0.35kUa/L) for either cockroach or dust mite allergens. ELISA and ImmunoCAP 
results were positively correlated for both dust mites and cockroach (Spearman’s correlation 
coefficient 0.32 and 0.29, respectively). There was no effect of intensive versus standard treatment on 
atopy (by SPT or IgE; Table 2). For all primary outcomes, there remained little evidence of a difference 
between trial arms in the “per protocol” analysis (Supplementary Table 1), or among age-groups 
(Supplementary Table 2), although RR for SPT responses to individual allergens increased in both the 
“per protocol” analysis, and in children<4 years.  
Impact of intensive versus standard anthelminthic treatment on secondary and exploratory 
outcomes 
Schistosoma mansoni infection prevalence was lower in intensive villages when assessed by stool Kato-
Katz (23% versus 39%, adjusted RR 0.70; 95%CI: 0.55-0.88; Table 3) and stool PCR (39% versus 60%, 
adjusted RR 0.76; 95%CI: 0.65-0.88), but urine CCA positivity remained high and similar across trial 
arms (both 85%; Table 3), indicating that intensive treatment was more effective than standard in 
reducing heavy intensity Schistosoma infections, particularly apparent in younger age groups, but had 
little impact on light infection prevalence (Figure 3A). Schistosoma infection was lower in both trial 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy761/5093172 by London School of H
ygiene & Tropical M
edicine user on 19 Septem
ber 2018
 14 
 
arms, compared to baseline: 49% and 23% pre- and post-intervention in intensive, 56% and 39% in 
standard.  Interim survey data suggested a greater initial reduction in intensive villages, which then 
plateaued, and a gradual reduction in standard villages (Figure 3B). STH prevalence was relatively 
low. Intensive treatment reduced hookworm prevalence; no significant reductions were seen for other 
nematodes (Table 3). There was no impact of intensive versus standard treatment on anthropometric 
or clinical outcomes, including hepatosplenomegaly assessed by palpation (Table 3) or ultrasound 
(among children; Supplementary Table 3).  The “per protocol” analysis did not yield any hitherto 
unseen differences (Supplementary Table 4).   
Serious adverse events 
77,739 praziquantel treatments and 102,219 albendazole treatments were given.  Four serious 
adverse events were reported, all among adults, within two days of treatment, two in each trial arm: 
gastrointestinal symptoms leading to hospitalisation (1) or requiring intravenous fluids (1); 
abdominal pain and vaginal bleeding in a non-pregnant woman (1); vaginal bleeding one day after 
treatment in a pregnant woman, followed by delivery three days later (probably premature) and 
subsequent neonatal death (1).  Clinic records suggested that this last woman had concurrent malaria 
but this remained unconfirmed.   
 
DISCUSSION 
We report the first trial to address community-level effects of intensive anthelminthic MDA in a high 
Schistosoma mansoni transmission setting. After three years, we found no effect of intensive, compared 
to standard, intervention on allergy-related or helminth-associated disease outcomes. Intensive, 
compared to standard, praziquantel achieved a substantial reduction in S. mansoni intensity, most 
marked after one year, but infection remained almost universal.  Intensive, compared to standard, 
albendazole achieved a modest reduction in hookworm prevalence, but had little impact on Trichuris 
or Strongyloides.   
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Prevalence of wheeze was lower than anticipated based on previous reports [25], limiting power for 
this outcome.  Understanding of “wheeze” in study communities was poor; there are no words for 
wheeze or asthma in the vernacular and asthma is rare. That said, there was no effect of intensive 
intervention on wheeze, and no increase in wheeze during the intervention (5% at baseline [13], 3% 
after three years).  These results provide reassurance that anthelminthic MDA is unlikely to have an 
immediate adverse effect on asthma among high-schistosomiasis-transmission communities, although 
no conclusions can be drawn on the impact of effective, universal, S. mansoni removal.   
SPT positivity was common. There was no increase in SPT positivity during the intervention (19% at 
baseline [13], 18% and 20% in the standard and intensive arms respectively after three years). There 
was a suggestion, especially in the “per protocol” analysis and in under-four-year-olds, that SPT 
responses increased with intensive treatment. This could be a chance finding, since a substantial 
number of (planned) statistical tests were conducted.  This warrants more detailed investigation as it 
may presage emergence of increased atopy and ARD when helminth infections are more completely 
cleared. The effect of treatment may have differed based on pre-treatment infection intensity [26]. We 
could not assess this hypothesis because our study was not a cohort of individual subjects.  
Despite our emphasis on schistosomiasis, and on long-term, community-based intervention, our 
results accord with previous, shorter-term trials focussing on STH [10]. However, it seems premature 
to conclude that high helminth prevalence has no causal link with low ARD prevalence in LICs, given 
strong effects and demonstrated mechanisms in animal models and experiments using human samples 
in vitro [27].  
The most obvious explanation for a lack of impact on allergy-related (or helminth-associated) disease 
is failure to clear helminth infections.  All villages were continuously exposed to S. mansoni-infested 
lake water because of lack of alternative safe water, involvement in fishing and open defaecation due 
to scarcity of latrines. Although single- and first-dose treatment were directly observed, compliance 
was imperfect; albendazole uptake in the standard arm was lower in rounds where praziquantel was 
given, indicating that villagers were averse to praziquantel side effects. Furthermore, we cannot rule 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy761/5093172 by London School of H
ygiene & Tropical M
edicine user on 19 Septem
ber 2018
 16 
 
out the possible role of reduced drug efficacy [28, 29]. However, as a differential effect on helminth 
intensity was achieved, particularly for schistosomiasis, our results cast doubt on the extent to which 
intensity reduction (without elimination) substantially modifies overall immunological or pathological 
effects in high-schistosomiasis-transmission settings.   
Other factors contributing to lack of impact on allergy-related outcomes may include long-term 
immunological effects of helminth exposure through persistence of antigen, or through epigenetic 
changes in immunological pathways [30]. Also, in tropical, low-income settings, numerous other 
exposures, including immunomodulating infections such as malaria, exposure to dirt and domestic 
animals, or the microbiome profile, may impact allergy-related outcomes, such that modifying 
helminth exposure alone may have limited impact [31].   
A recent meta-analysis examined effects of treating schistosomiasis on related morbidity [32]. The 
results indicated wide-ranging benefits, with increased impact when egg reduction rates were greatest 
and, for anaemia and chronic morbidities, when treatments were repeated over periods of greater 
than 24 months.  Thus we were disappointed that, despite differential reduction in schistosome 
intensity, we found no evidence that three years’ intensive (compared to standard) intervention 
achieved improvement in any morbidity measure.  This adds to the evidence base showing limited 
effects of MDA on such outcomes at community-level.  We identified surprisingly little severe 
Schistosoma-related morbidity in this community, despite intense infection, consistent with earlier 
work from Lake Victoria communities; it is possible that intensive intervention would have greater 
benefit in settings (such as Lake Albert) where severe pathology is more common [33].  
Our experience emphasises that MDA may struggle to eliminate helminths as a public health problem, 
especially in high-transmission environments.  The substantial decline in S. mansoni infection (by 
Kato-Katz) achieved in year-one led us to hope that intensive intervention could make an important 
contribution to schistosomiasis control in these challenging “hot-spots”.  The subsequent plateau and 
persistent infection (by CCA) were disheartening. This phenomenon (a large drop in prevalence 
followed by a subsequent plateau) has also been reported in Kenyan districts bordering Lake Victoria 
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[34]. Besides reinfection, the possibility of selection for praziquantel-resistant or tolerant strains is of 
concern [35].  A radically different approach, with complementary interventions including improved 
water supply and sanitation, behaviour change and vector control is needed: and an effective vaccine 
against schistosomiasis [36].   
Observational analyses addressing effects of helminths remain limited by confounding by poverty and 
environment.  Our strategy aimed to pinpoint helminth effects by randomising their treatment, but 
was constrained by difficulties in achieving removal.  Trials designed so that helminths are cleared, in 
settings where re-infection can be avoided, and with substantial follow-up, are needed for a full 
understanding of the risks and benefits of “de-worming”. 
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Table 1. Characteristics of outcome survey participants 
      Standard arm 
 
Intensive arm 
Cluster-level characteristics   (n=13)      (n=13)   
Mean no. of households per village (range) 307 (124-882) 
 
289 (87-544) 
Mean no. of participating households (range) 55 (48-63) 
 
54 (48-64) 
Mean no. of individuals resident in participating households (range) 137 (89-161) 
 
137  (85-177) 
Mean no. of individuals included in analysis (range) 129 (84-150) 
 
129 (79-169) 
Villages with any public toilets 5 38% 
 
6 46% 
Median no. of public toilets (range) 0 (0-16) 
 
0 (0-20) 
Median no. of private toilets (range) 8 (0-59) 
 
3  (1-29) 
Water supply other than lake  3 23% 
 
5 38% 
 
Piped water 2 67% 
 
2 40% 
 
River or open spring 1 33% 
 
2 40% 
 
Open well 0 0% 
 
1 20% 
Household-level characteristics (n=714)     (n=705)   
Median no. of household members (IQR) 2 (1-3) 
 
2 (1-3) 
Individual-level characteristics (n=1675)     (n=1675)   
Sex, male 881 53% 
 
857 51% 
Age in years, grouped 
     
 
0-4 283 17% 
 
264 16% 
 
5-9 173 10% 
 
219 13% 
 
10-14 66 4% 
 
115 7% 
 
15-19 102 6% 
 
79 5% 
 
20-24 212 13% 
 
179 11% 
 
25-29 239 14% 
 
216 13% 
 
30-34 198 12% 
 
211 13% 
 
35-39 175 10% 
 
140 8% 
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40-44 86 5% 
 
106 6% 
 
45+ 141 8% 
 
146 9% 
Place of birth (mv 9, 19)
a
 
     
 
This fishing village 439 26% 
 
477 29% 
 
Other fishing village 48 3% 
 
20 1% 
 
Other rural village 1021 61% 
 
1002 61% 
 
Town 127 8% 
 
127 8% 
 
City 31 2% 
 
30 2% 
Has remained in village during intervention period (mv 9, 19) 1190 71% 
 
1170 71% 
Has lived in other trial arm during intervention period (mv 9, 19) 18 1% 
 
32 2% 
Maternal history of allergic diseases (mv 9, 19) 
            No history 1193 72% 
 
1204 73% 
       History of asthma, eczema or allergies 258 15% 
 
266 16% 
 
Don't know 215 13% 
 
186 11% 
Paternal history of allergic diseases (mv 9, 19) 
     
 
No history 1248 75% 
 
1244 75% 
 
History of asthma, eczema or allergies 145 9% 
 
155 9% 
 
Don't know 273 16% 
 
257 16% 
Occupation, grouped by type  (mv 8, 19) 
     
 
Child, not at school 289 17% 
 
275 17% 
 
Student 257 15% 
 
345 21% 
 
Housewife 120 7% 
 
101 6% 
 
Fishing or lake related 564 34% 
 
467 28% 
 
Shops, saloons, artisans, service providers 118 7% 
 
102 6% 
 
Bars, restaurants, food providers, entertainment 114 7% 
 
103 6% 
 
Agricultural, lumbering, charcoal 157 9% 
 
201 12% 
 
Professional 11 1% 
 
19 1% 
 
Unemployed 37 2% 
 
43 3% 
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Treated with albendazole in the last 12 months (mv 360, 253) 1291 98% 
 
1404 99% 
Treated with praziquantel in the last 12 months (mv 355, 253) 989 75% 
 
1318 93% 
Malaria treatment with coartem (mv 190, 167) 708 42% 
 
747 45% 
Malaria positivity by blood smear (P. falciparum) (mv 213, 214) 50 3% 
 
52 4% 
Individuals aged 13 years and over (n=1176)     (n=1112)   
Frequency of lake contact (mv 9, 19) 
     
 
Every day 911 78% 
 
776 71% 
 
Almost every day 126 11% 
 
147 13% 
 
Once a week 95 8% 
 
124 11% 
 
Once a month 30 3% 
 
35 3% 
 
Less than once a month 4 0% 
 
10 1% 
 
Never 1 0% 
 
1 0% 
Individuals aged 18 years and over (n=1116)     (n=1041)   
HIV+  (mv 173, 176) 192 20% 
 
198 23% 
 
HIV+ on ART 90 47% 
 
103 52% 
 
HIV+ not on ART 93 48% 
 
90 45% 
 
HIV+ not known if receiving ART 9 5% 
 
5 3% 
a
Figures in parentheses indicate missing values in the standard and intensive arm, respectively 
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Table 2. Impact of intensive versus standard anthelminthic treatment on primary outcomes 
  
n/N (%) / geometric mean 
 
Unadjusted 
 
Adjusted for outcome at 
baseline, age and sexa 
Outcome 
Standard Intensive 
 
RR/GMR 
(95% CI) 
p-
value  
RR/GMR 
(95% CI) 
p-
value 
 
Wheeze (age≥5 years)b 44/1384 (3.2%) 43/1392 (3.1%) 
 
1.06 (0.61, 1.87) 0.82 
 
1.11 (0.64, 1.93) 0.69 
 
Wheeze (age<5 years) 6/284 (2.1%) 3/264 (1.1%) 
    
 
 
Atopy (SPT) 
      
 
 
 
SPT positivity to any allergen  273/1514 (18.0%) 303/1523 (19.9%)  1.09 (0.83, 1.44) 0.51 
 
1.10 (0.85, 1.42) 0.46 
 
SPT positivity to Dermatophagoides 162/1514 (10.7%) 164/1523 (10.8%)  0.98 (0.72, 1.35) 0.92 
 
1.00 (0.74, 1.36) 0.99 
 
SPT positivity to Blomia tropicalis 102/1514 (6.7%) 127/1522 (8.3%)  1.26 (0.83, 1.90) 0.26 
 
1.27 (0.85, 1.91) 0.22 
 
SPT positivity to German cockroach 156/1513 (10.3%) 194/1522 (12.8%)  1.24 (0.87, 1.77) 0.20 
 
1.22 (0.87, 1.71) 0.21 
Atopy (IgE detected by ImmunoCAP) 
        
 
Dermatophagoides or cockroach positivity 
(>0.35kUa/L) 
214/390 (54.9%) 210/390 (53.9%)  0.97 (0.83, 1.13) 0.67 
 
0.96 (0.82, 1.12) 0.60 
 
Dermatophagoides positivity (asIgE>0.35kUa/L) 134/390 (34.4%) 130/390 (33.3%)  0.95 (0.76, 1.20) 0.67 
 
0.96 (0.77, 1.19) 0.68 
 
German cockroach positivity (asIgE>0.35kUa/L) 201/390 (51.5%) 192/390 (49.2%)  0.94 (0.80, 1.11) 0.47 
 
0.94 (0.79, 1.11) 0.42 
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aAtop
y 
outco
mes 
asses
sed 
by IgE were adjusted for age and sex only; bFor this outcome, a natural log transformation was applied to village level proportions to correct skewed distributions and data in parentheses are 
geometric means of village proportions; clog10(+0.001) transformation at individual level; dlog10(+1) transformation at individual level; RR: risk ratio; GM: geometric mean; GMR: geometric 
mean ratio; CI: confidence interval 
 
 
  
 
Concentration of asIgE to Dermatophagoides (kUa/L)c GM: 0.158 GM: 0.129 
 
0.78 (0.51, 1.17) 0.22 
 
0.77 (0.52, 1.13) 0.17 
 
Concentration of asIgE to German cockroach (kUa/L)c GM: 0.342 GM: 0.289 
 
0.82 (0.55, 1.22) 0.31 
 
0.81 (0.55, 1.20) 0.28 
Atopy (IgE detected by in house ELISA) 
        
 
Concentration of asIgE to Dermatophagoidesd GM: 60.3 GM: 73.8 
 
1.13 (0.36, 3.50) 0.83 
 
1.17 (0.39, 3.51) 0.78 
  Concentration of asIgE to German cockroachd GM: 72.4 GM: 161.0 
 
1.98 (0.59, 6.63) 0.25 
 
1.51 (0.45, 5.04) 0.49 
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Table 3. Impact of intensive versus standard anthelminthic treatment on helminths, clinical outcomes, hepatosplenomegaly by palpation, and 
anthropometry 
 
n/N (%) / arithmetic mean 
 
Unadjusted 
 
Adjusted for outcome at 
baseline, age and sex 
Outcome 
Standard Intensive 
 
RR/mean difference 
(95% CI) 
p-
value  
RR/mean difference 
(95% CI) 
p-value 
Helminth infections 
        
 
Schistosoma mansoni, stool Kato Katz 523/1355 (38.6%) 323/1396 (23.1%) 
 
0.64 (0.43, 0.94) 0.02 
 
0.70 (0.55, 0.88) 0.003 
Schistosoma mansoni, stool PCR 797/1353 (59.9%) 541/1394 (38.8%)  0.68 (0.52, 0.89) 0.007  0.76 (0.65, 0.88) 0.001 
 
Schistosoma mansoni, urine CCA 
1229/1444 
(85.1%) 
1216/1435 
(84.7%)  
0.99 (0.91, 1.08) 0.85 
 
1.00 (0.93, 1.08) 0.93 
 
Hookworm, stool PCRa 147/1353 (10.9%) 112/1394 (8.0%) 
 
0.54 (0.28, 1.02) 0.06 
 
0.55 (0.31, 1.00) 0.05 
 
Strongyloides stercoralis, stool PCR 112/1353 (8.3%) 78/1394 (5.6%) 
 
0.74 (0.50, 1.11) 0.14 
 
0.78 (0.54, 1.14) 0.21 
 
Trichuris trichiura, stool Kato Katza 137/1355 (10.1%) 108/1396 (7.7%) 
 
0.91 (0.40, 2.09) 0.82 
 
0.85 (0.48, 1.50) 0.55 
 
Ascaris lumbricoides, stool Kato Katz 11/1355 (0.8%) 3/1396 (0.2%) 
      
Clinical outcomes 
        
 
Visible flexural dermatitis 1/1558 (0.1%) 4/1553 (0.3%) 
      
 
Haemoglobin 14.0 13.9 
 
-0.06 (-0.37, 0.25) 0.70 
 
0.00 (-0.24, 0.25) 0.97 
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Anthropometry 
        
 
Height-for-age z-score, age 1-19 years -0.48 -0.49 
 
-0.01 (-0.20, 0.19) 0.95 
 
0.02 (-0.16, 0.20) 0.83 
 
Weight-for-age z-score, age 1-10 years -0.06 -0.17 
 
-0.11 (-0.31, 0.09) 0.27 
 
-0.05 (-0.23, 0.12) 0.52 
Weight-for-height z-score, age 1-5 years 0.15 0.19  -0.09 ( -0.43, 0.26) 0.62  -0.06 (-0.40, 0.28) 0.72 
Hepatosplenomegaly, palpation 
        
 
Hepatomegaly, palpation 100/1546 (6.5%) 98/1546 (6.3%) 
 
0.97 (0.71, 1.32) 0.83 
 
0.96 (0.70, 1.32) 0.80 
 
Splenomegaly, palpation 87/1549 (5.6%) 63/1547 (4.1%) 
 
0.73 (0.43, 1.25) 0.20 
 
0.70 (0.43, 1.15) 0.13 
 
Hepatosplenomegaly, palpation1 22/1548 (1.4%) 14/1548 (0.9%) 
 
0.85 (0.52, 1.39) 0.49 
 
0.78 (0.47, 1.30) 0.33 
Reported clinical outcomes (exploratory) 
        
 
Urticaria, last 12 months 162/1667 (9.7%) 172/1656 (10.4%) 
 
1.06 (0.86, 1.30) 0.59 
 
1.06 (0.88, 1.27) 0.51 
 
Rhinitis, last 12 months 78/1667 (4.7%) 74/1656 (4.5%) 
 
1.02 (0.73, 1.42) 0.92 
 
1.00 (0.74, 1.36) 0.99 
aFor this outcome, a natural log transformation was applied to village level proportions to correct skewed distributions; RR: Risk Ratio; CI: confidence interval; CCA: circulating cathodic 
antigen; PCR: polymerase chain reaction 
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Figure 1. Praziquantel and albendazole treatment coverage, by trial arm and treatment round 
Figure 2. Trial flowchart 
Figure 3. A: Intensity of schistosomiasis infection in the outcome survey, by age group and trial 
arm. B: Prevalence of schistosomiasis infection over time (pre-intervention baseline survey, 
interim survey at one year, interim survey at two years, outcome survey at three years), by trial 
arm. Panel A shows prevalence assessed by Kato Katz examination of a single stool sample (KK); 
polymerase chain reaction (PCR); and urine circulating cathodic antigen (CCA).  Panel B shows the 
mean of village prevalences over time +/- 95% confidence intervals, assessed using KK analysis of a 
single stool sample (with duplicate slides) at each time point 
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Figure 1 
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Figure 2 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy761/5093172 by London School of H
ygiene & Tropical M
edicine user on 19 Septem
ber 2018
 35 
 
Figure 3A 
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Figure 3B 
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